Pfizer’s pipeline pruning ends early-stage STING trial

Pfizer was studying PF-07820435, an orally available agonist of the STING protein, for solid tumors.
Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update to the study’s clinicaltrials.gov page on Thursday.